Aspects of the Clinical use of the Import-Substituted Radiopharmaceutical Agent 18F-PSMA in Prostate Cancer

DOI: 10.47026/2413-4864-2024-4-22-35

UDC: 615.31:546.05
BBC: 53.6

Baryshnikov I.A., Udalov Yu.D., Sychev P.V., Mayakova E.V., Maltseva T.Yu., Akramova A.A.

Aspects of the Clinical use of the Import-Substituted Radiopharmaceutical Agent 18F-PSMA in Prostate Cancer

Keywords: domestic radiopharmaceutical agents, positron emission tomography combined with computed tomography, prostate cancer, 18F-PSMA

One of the most common types of radionuclide studies, which are gaining traction in oncology, is positron emission tomography combined with computed tomography. The most significant and promising radiopharmaceutical agent in the radionuclide diagnosis of prostate cancer is 18F-PSMA. A high sensitivity and specificity of this radiopharmaceutical agent for prostate cancer are due to the prostate-specific membrane antigen, which is the second type of transmembrane glycoprotein with a high expression in endothelial cells during neoangiogenesis. The purpose is to develop a domestic import–substituted radiopharmaceutical agent 18F-PSMA, manufactured in the system of the Federal Medical and Biological Agency of Russia using domestic substances and excipients. Materials and methods. The syntheses were carried out on the Fastlab GE Healthcare module. This module has been repeatedly used to manufacture the radiopharmaceutical agent 18F-PSMA-1007 using original ABX cassettes. The reagent kit consisted of a vial with the precursor 18F-PSMA-1007, a vial with dimethyl sulfoxide for dissolving the precursor, and a vial with a solution of tetrabutylammonium in ethanol. Additional vials used outside the cassette and connected by connecting tubes with needles contained ethanol solutions with concentrations of 5 and 30%, a phosphate buffer solution. A QMA (quaternary methylamonium) cartridge was used to isolate fluorine-18. Sequentially connected PS-H⁺ and C18 extraction cartridges were used to isolate and purify the final product. Consumables included a «skeleton» with rotary valves, a housing, a three-necked reactor flask, glass vials, connecting tubes and adapters. Results. The process of synthesizing a radiopharmaceutical agent using domestic reagents was similar to the original one. A comparative analysis of the synthesis charts, a comparative analysis of the activity and yield of RFP made from domestic and imported reagents, and an assessment of radiochemical purity were carried out. The physiological and pathological distribution of the domestic radiopharmaceutical agent, as well as its comparison to the original drug, were carried out in the clinical part of the study, during which no side effects and adverse events were noted in patients. Conclusions. The radiopharmaceutical preparation made from domestic reagents using adapted technology for the original cassette is identical to the original in all quality indicators and corresponds to approved regulatory values.

References

Aksel’ E.M., Matveev V.B. Statistika zlokachestvennykh novoobrazovanii mochevykh i muzhskikh polovykh organov v Rossii i stranakh byvshego SSSR [Statistics of malignant neoplasms of the urinary and male genital organs in Russia and the countries of the former USSR]. Onkourologiya, 2019, vol. 15, no. 2, pp. 15–24. DOI: 10.17650/1726-9776-2019-15-2-15-24.
Zukov R.A., Vyaz’min V.V., Chanchikova N.G. Diagnosticheskie vozmozhnosti PET/KT s 18B-PSMA u patsientov s podozreniem na rak predstatel’noi zhelezy [Diagnostic capabilities of PET/CT with 18B-PSMA in patients with suspected prostate cancer]. Effektivnaya farmakoterapiya, 2022, vol. 18, no. 13, pp. 6– DOI 10.33978/2307-3586-2022-18-13-6-10.
Kodina G.E, Malysheva A.O. Kontrol’ kachestva radiofarmatsevticheskikh preparatov v meditsinskikh organizatsiyakh [Quality control of radiopharmaceuticals in medical organizations]. Razrabotka iregistratsiya lekarstvennykh sredstv, 2017, no. 1(18), pp. 88–92.
Bozhko N.S., Antropov C.Yu., Korostin S.V. et al. Otsenka tochnosti opredeleniya radiokhimicheskoi chistoty radiofarmpreparatov s ispol’zovaniem skanera khromatogramm [Assessment of the accuracy of determining the radiochemical purity of radiopharmaceuticals using a chromatogram scanner]. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’, 2014, vol. 59, no. 4, pp. 58–66.
Dolbov A.L., Stanzhevskii A.A., Maistrenko D.N. et al. PET/KT-vizualizatsiya raka predstatel’noi zhelezy. Sovremennye varianty radiofarmpreparatov [PET/CT imaging of prostate cancer. Modern versions of radiopharmaceuticals]. Onkologicheskii zhurnal: luchevaya diagnostika, luchevaya terapiya, 2021, vol. 4, no. 2, pp. 23–36. DOI: 10.37174/2587-7593-2021-4-2-23-36.
Rumyantsev P.O. Vozrastayushchaya rol’ metodov funktsional’noi vizualizatsii dlya navigatsii distantsionnoi radioterapii i brakhiterapii na primere raka predstatel’noi zhelezy [The increasing role of functional imaging methods for navigation of external beam radiotherapy and brachytherapy using the example of prostate cancer]. Digital Diagnostics, 2021, vol. 2, no. 4, pp. 488−497. DOI: 10.17816/DD96197.
Vyaz’min V.V., Zukov R.A., Chanchikova N.G. et al. Sovremennye vozmozhnosti PET/KT v diagnostike raka predstatel’noi zhelezy [Modern capabilities of PET/CT in the diagnosis of prostate cancer]. Sibirskii onkologicheskii zhurnal, 2021, vol. 20, no. 5, pp. 115–122. DOI: 10.21294/1814-4861-2021-20-5-115-122.
Kaprin A.D., Starinskii V.V., Shakhzadova A.O., eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu [The state of cancer care for the population of Russia in 2021]. Moscow, 2022, 239 p.
Mironov S.P., Vasilenko E.I., Cholak P.M. et al. Stsintigrafiya skeleta pri otsenke otveta metastazov raka predstatel’noi zhelezy na androgennuyu deprivatsionnuyu terapiyu [Skeletal scintigraphy in assessing the response of prostate cancer metastases to androgen deprivation therapy]. Vestnik rentgenologii i radiologii, 2021, vol. 102, no. 4, pp. 232–239. DOI: 10.20862/0042‑4676‑2021‑102‑4-232-239.
Abdulla R., Ahmed M. MRI Limitations: the Main Aspects and reSolving Techniques. Indian Journal of Applied Research, 2020, vol. 10(9), pp. 71–73.
Anand S.S., Singh H., Dash A.K. Clinical Applications of PET and PET-CT. Med J Armed Forces India, 2009, vol. 65(4), pp. 353–358. DOI: 10.1016/S0377-1237(09)80099-3.
Chandekar K.R., Singh H., Kumar R. et al. Comparison of 18 F-PSMA-1007 PET/CT With 68 Ga-PSMA-11 PET/CT for Initial Staging in Intermediate- and High-Risk Prostate Cancer. Clin Nucl Med., 2023, vol. 48(1), pp. e1–e8. DOI: 10.1097/RLU.0000000000004430.
Gallach M., Mikhail Lette M., Abdel-Wahab M. et al. Addressing Global Inequities in Positron Emission Tomography-Computed Tomography (PET-CT) for Cancer Management: A Statistical Model to Guide Strategic Planning. Med Sci Monit., 2020, vol. 26, e926544. DOI: 10.12659/MSM.926544.
International Association of Cancer Registries (GLOBOCAN). Available at: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=101&Itemid=578.
Kostakoglu L., Coleman M., Leonard J.P. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med., 2002, vol. 43(8), pp. 1018–1827.
Krarup M.M.K., Fischer B.M., Christensen T.N. New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Semin Nucl Med., 2022, vol. 52(6), pp. 781–796. DOI: 10.1053/j.semnuclmed.2022.05.002.
Mountz J.M., Liu H.G., Deutch G. Neuroimaging in cerebrovasular disorders: measurement of cerebral physiology after stroke and assessment of recovery. Sem Nucl Med., 2003, vol. 33, pp. 56–60.
Perini E.A., Skopchenko M., Hong T.T. et al. Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries. Curr Radiopharm, 2019, vol. 12(3), pp. 187–200. DOI: 10.2174/1874471012666190328164253.
Rowe S.P., Drzezga A., Neumaier B. et al. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med., 2016 Oct, vol. 57(Suppl 3), pp. 90S–96S. DOI: 10.2967/jnumed.115.170175.
Sadaghiani M.S., Baskaran S., Gorin M.A. et al. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis. J Nucl Med., 2024, vol. 65(7), pp. 1007–1012. DOI: 10.2967/jnumed.124.267417.

About authors

Baryshnikov Ivan A.: Candidate of Medical Sciences, Radiologist, Topometric Preparation Unit, Proton and Photon Center, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad (baryshnikovia@fnkcrio.ru; ORCID: https://orcid.org/0000-0002-8903-6012)

Udalov Yuri D.: Doctor of Medical Sciences, Director General, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad; Professor, Department of Oncology and Radiation Diagnostics, Ulyanovsk State University, Russia, Dimitrovgrad (udalov@Fvcmrmail.ru; ORCID: https://orcid.org/0000-0002-9739-8478)

Sychev Petr V.: Head of the Nuclear Medicine Center, Radiologist, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad (sychevpetr@gmail.com; ORCID: https://orcid.org/0000-0003-3965-4661)

Mayakova Elena V.: Deputy Director General for Medical Affairs, Chief Physician, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad (mayakovaev@fvcmrfmba.ru; ORCID: https://orcid.org/0000-0001-5551-818X)

Maltseva Tatyana Yu.: Head of the Department for Quality Control and Assurance of Radioisotope Products of the Nuclear Medicine Center, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad (maltsevatj@fvcmrfmba.ru; ORCID: https://orcid.org/0000-0002-6809-5961)

Akramova Anna A.: Radiologist, Department of Radionuclide Diagnostics of the Center for Nuclear Medicine, Federal Scientific Clinical Center for Medical Radiology and Oncology, Russia, Dimitrovgrad (akramova.an@yandex.ru; ORCID: https://orcid.org/0009-0001-6632-0723)

Article link

Baryshnikov I.A., Udalov Yu.D., Sychev P.V., Mayakova E.V., Maltseva T.Yu., Akramova A.A. Aspects of the Clinical use of the Import-Substituted Radiopharmaceutical Agent 18F-PSMA in Prostate Cancer [Electronic resource] // Acta medica Eurasica. – 2024. – №4. P. 22-35. – URL: https://acta-medica-eurasica.ru/en/single/2024/4/3/. DOI: 10.47026/2413-4864-2024-4-22-35.

Single article

Baryshnikov I.A., Udalov Yu.D., Sychev P.V., Mayakova E.V., Maltseva T.Yu., Akramova A.A.